| Literature DB >> 26198587 |
Ingris Pelaez1, Claudia Infante2, Rosana Quintana3.
Abstract
Early diagnosis and treatment of rheumatoid arthritis (RA) depends on the degree of fit between the characteristics of the patients and those of the health services. Ensuring timely assessment and treatment is the ideal medical care of RA. The reasons that underlay delays and the help-seeking trajectories are contextually determined. This study aims to identify the empirical evidence related to the help-seeking process and delay in RA in Latin America and to create a comprehensive model integrating the RA medical care processes of help-seeking and delay in a mixed health care system with variable accessibility. Non-systematic literature review of studies with both quantitative and qualitative methodology was conducted. Most of the research about delay and its associated variables have been undertaken in European countries and with White population and cannot be translated to the Latin America context where this research is almost inexistent. These countries have a completely different social context, and for most of the population, the health services are insufficient, inaccessible, fragmented, limited, and inequitable. Our results also show that in RA medical care utilization research, the theories and measurements of the constructs of illness trajectories, help-seeking, and accessibility are not integrated. We offer a conceptual framework that integrates help-seeking trajectories, delay, and accessibility of RA medical health services. If research on RA service utilization is to be undertaken in these countries, there is a need for a comprehensive framework than can enable researchers to integrate and contextualize the study of the problems within broad theoretical and methodological perspectives.Entities:
Keywords: Accessibility; Delay; Health care system; Help-seeking; Illness trajectory; Latin American; Rheumatoid arthritis
Mesh:
Year: 2015 PMID: 26198587 PMCID: PMC4617855 DOI: 10.1007/s10067-015-3013-z
Source DB: PubMed Journal: Clin Rheumatol ISSN: 0770-3198 Impact factor: 2.980
Fig. 1Methods of review. Greenhalgh [22]
Fig. 2RA trajectories of help-seeking at the pre-patient phase
Summary and analysis of quantitative studies
| Author, year (ref) | Objectives | Country | Definition of delay | Results | Variables associated with longer delay |
|---|---|---|---|---|---|
| Irvine S et al., 1999 [ | To study the delay in starting DMARDs in patients with RA, and any changes in medical practice between 1980 and 1997 | UK | 1. Delay from symptoms onset to referral by a GP and time from referral letter to clinic visit | 1. Median months: | The length of time between symptoms onset and GP referral is dependent on two variables: the delay from symptom onset to consultation with a GP and the time taken for the GP to decide that specialist assessment is required |
| Hernández-García C et al., 2000 [ | To study demographic and clinical variables associated with a longer delay in DMARD therapy initiation in a cohort of patients with RA | Spain | 1. Time between symptoms onset and first rheumatologist encounter | Median months (range) | Delay to DMARD therapy: time between symptoms onset and first rheumatologist visit and years of education. |
| Palm Ø and Purinszky E, 2005 [ | Evaluate lag times between disease onset and rheumatological encounter in patients with RA | Norway | 1. Time between onset of symptoms and the first encounter with a physician (“patient delay”); | Median weeks (range) | “Provider delay” was significantly longer in women than in men. The “provider delay” was longer than the “hospital delay” in men and women |
| Clemente D et al., 2007 [ | To analyze changes in the lag time to first DMARD prescription since onset of symptoms of RA over the last 2 decades in Spain | Spain | Time between symptoms onset and first DMARD therapy | Median months (range) | Delay from symptoms onset to consultation with a GP depending on SJC and accessibility to the health care system |
| Kumar K et al., 2007 [ | To study the delay from the time of symptoms onset to assessment by a rheumatologist in patients with RA and to determine the contributions of patient and physician-related factors to this delay | UK | 1. Time taken for patients with symptoms to consult their GP (patient-related factors) | Median weeks (IQR) | Patient-related factors leading to a delay in consulting primary care physicians are the principal reasons for the delay in patients with RA being seen by rheumatologists |
| Feldman DE et al., 2007 [ | Determine whether patients suspected of having new-onset RA consulted with a rheumatologist, to document any delay in these consultations, and to determine factors associated with prompt consultation | Canada | Time between first diagnostic visit and consultation with the rheumatologist | Median days (IQR) | Older age, lower socioeconomic status, less education, and less access to health services |
| Kumar K et al., 2010 [ | Determine the influence of ethnicity on delay | UK | 1. Time from the onset of symptoms to a patient’s being assessed in primary care | Median weeks (IQR) | Patient delay was significantly longer in patients of South Asian origin than in other patients |
| van der Linden MP et al., 2010 [ | Examine the association between delay in assessment by a rheumatologist, rates of joint destruction, and probability of achieving DMARD-free remission in patients with RA | Holland | 1. Time from onset of symptoms and a patient’s being seen by a GP (patient delay) | Median weeks (IQR) | Delay in assessment by a rheumatologist: older age, gradual symptoms onset, involvement of small joints, presence of anti-CCP-2 and IgM-RF, and lower CRP levels |
| Raza K et al. , 2011 [ | Quantify delays in assessment of patients with RA across several European countries and to identify whether the principal reasons for delay varied between countries | Germany, UK, Greece, Sweden, Czech Republic, Austria, Poland, and Switzerland | 1. Delay from symptoms onset to request to HCP of contact | Range (min-max) inter countries weeks | Delay of the initial HCP in referring to a rheumatologist was an important contributor to overall delay. In some centers the initial HCP of contact was frequently an orthopedic surgeon |
| Jamal S et al. , 2011 [ | Determine the proportion of patients with RA seen by rheumatologists and treated with DMARD within 3 months of symptoms onset | Canada | 1. Time from symptom onset to DMARD initiation | Median months (IQR) | Only baseline SJC was found to significantly predict treatment with DMARD within 3 months of symptom onset |
| Rodriguez-Polanco E et al., 2011 [ | Estimate the lag time between onset of symptoms, diagnosis, and initiation of DMARD treatment | Venezuela | 1. Time between initiation of symptoms and diagnosis of RA | Median months (SD) | Lower socioeconomic class, lower level of education, first consultation in a public health center, being seen by a GP or an orthopedist as first consultant |
| van Nies JA et al., 2013 [ | Assess the motivations and the urgency with which patients with arthralgia seek medical help | Holland | Time between symptoms onset and the first visit to the GP | Median weeks (range) | A prolonged delay in seeking help was associated with a gradual onset of symptoms, younger age in women, and the perception that symptoms are not serious |
| van Nies JA et al., 2013 [ | Investigated the efficacy of the EARC to decrease the GP delay and consequently reduce the total delay in identifying arthritis | Holland | Time between the first visit to the GP and the first visit to a rheumatologist (delay GP) | Median weeks (range) | Delay was longer before the implementation of EARC, which involved training GPs to recommend an early referral |
| Villeneuve E et al., 2013 [ | A systematic literature review to identify effective strategies to reduce delays in the diagnosis and management of IA, in particular RA | UK | 1. From to symptoms onset to assessment in primary care | Unreported | Lack of patient education on recognizing the symptoms, inadequate GP and health professional training programs and lack of implementation of EARC |
| Widdifield J et al., 2014 [ | Estimate the percentage of patients with RA who were seen by a rheumatologist within 3, 6, and 12 months of suspected diagnosis by GP | Canada | Time to be seen by a rheumatologist in patients with RA within 3, 6, and 12 months | 3 months, 59 % | The strongest independent with lower frequency of rheumatology visits: patients who lived at remote distances from rheumatologists and male family physicians |
| De Cock D et al., 2014 [ | Quantify the different stages of delay before RA treatment in different rheumatology centers and to explore influencing factors | Belgium | 1. Patient delay according to the patienta
| Median weeks (IQR) | Total delay: public hospital. Delay were inversely related to disease activity and severity parameters |
| Badley EM et al., 2015 [ | Examine the per capita rate of visits to rheumatologists as an indicator of access to care for all arthritis and inflammatory arthritis | Canada | 1. Rate of visits to GP | Median (range) rate per 1,000 inhabitants | Patients living in areas with low access to GP or low SES were less likely to have office visits to rheumatologists |
| Molina E et al., 2015 [ | Examine the association of SES and delays in DMARD treatment with clinical measures in RA patients | US | Time between symptoms onset and DMARD initiation | Median years (SD) | Lower SES, Hispanic origin, public hospitals and distance from the patient’s home to where they received their rheumatologic care |
| Sørensen J et al., 2015 [ | Examine the delay in diagnosis of RA, PSA, and AS changed from year 2000 to 2011 (Danish DANBIO registry) | Denmark | Time between onset of symptoms to diagnosis of RA, PSA, and AS | Median months (SD) | Female patients, older age and lower socioeconomic status |
IQR interquartile range, SD standard deviation, CRP C-reactive protein, DMARD disease-modifying antirheumatic drugs, GP general practitioner, RA rheumatoid arthritis, PSA psoriatic arthritis, AS ankylosing spondylitis, CCP anti-cyclic citrullinated peptide, RF rheumatoid factor, HCP health care professional, EARC Early Arthritis Recognition Clinic, SES socioeconomic status, SJC swollen joint count
aTime elapsed between symptoms onset as viewed by the patient and first visit to a GP regarding RA symptoms
bTime elapsed between symptoms onset as observed by a GP and first visit to a GP regarding RA symptoms
cTime elapsed between first visit to a GP and referral to a rheumatologist
dTime elapsed between referral to and first screening by a rheumatologist
eTime elapsed between first screening by a rheumatologist and start of treatment
fTime elapsed between referral to a rheumatologist and start of treatment
gTime elapsed between diagnosis of RA and start of treatment
hTime elapsed between symptoms onset and start of treatment
Fig. 3Conceptual framework of the intersection between the help-seeking processes and the domains of accessibility